Chelsea Johnson

Chelsea Place Johnson is a principal and focuses on new company formation across areas of unmet medical need.
Chelsea is a co-founder and board member at Judo Bio, contributed to the early build and is a board observer for Rectify Pharmaceuticals, K36 Therapeutics, and Chroma Medicine, and is a board observer for Sionna Therapeutics and Scorpion Therapeutics.
Prior to joining Atlas Venture in 2019, Chelsea was a member of the Tango Therapeutics founding team, working in business development for the synthetic lethality-focused oncology company.
Prior to Tango, Chelsea was a senior associate at Third Rock Ventures where she contributed to the formation of multiple new biotech companies.
Chelsea obtained her PhD from the Biological and Biomedical Sciences program at Harvard University where she received the Ruth L.
Kirschstein National Research Service Award.
Her doctoral work in the lab of Dr. Levi Garraway focused on genomic and functional genomic studies of uveal melanoma.
Chelsea received a BA in biology from Dartmouth College and was elected Phi Beta Kappa.
Chelsea spends her free time outdoors with her husband and young children, including on the golf course, ski slopes, and playground.